Neurocrine Biosciences (NBIX) Downgraded by ValuEngine to Hold

Neurocrine Biosciences (NASDAQ:NBIX) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday, ValuEngine reports.

Other equities analysts have also issued reports about the stock. Zacks Investment Research raised shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating and set a $105.00 price objective on the stock in a research report on Wednesday, April 10th. Barclays reissued a “buy” rating and issued a $110.00 price objective on shares of Neurocrine Biosciences in a research report on Friday, March 29th. Evercore ISI began coverage on shares of Neurocrine Biosciences in a research report on Thursday. They issued an “outperform” rating on the stock. Oppenheimer set a $105.00 price objective on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research report on Tuesday, January 29th. Finally, JPMorgan Chase & Co. lowered shares of Neurocrine Biosciences from an “overweight” rating to a “neutral” rating and increased their price objective for the company from $97.00 to $100.00 in a research report on Wednesday, January 23rd. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $103.48.

NBIX stock traded down $1.43 during trading hours on Monday, reaching $84.81. The stock had a trading volume of 625,300 shares, compared to its average volume of 892,451. The stock has a market cap of $7.78 billion, a P/E ratio of 385.50, a P/E/G ratio of 27.82 and a beta of 1.87. The company has a debt-to-equity ratio of 0.81, a current ratio of 8.36 and a quick ratio of 8.24. Neurocrine Biosciences has a fifty-two week low of $64.72 and a fifty-two week high of $126.98.



Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Tuesday, February 5th. The company reported $0.19 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.14 by $0.05. The company had revenue of $131.49 million for the quarter, compared to analyst estimates of $132.32 million. Neurocrine Biosciences had a net margin of 4.68% and a return on equity of 5.06%. The company’s revenue was up 39.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.07 earnings per share. As a group, equities research analysts anticipate that Neurocrine Biosciences will post 0.13 EPS for the current fiscal year.

In other Neurocrine Biosciences news, CEO Kevin Charles Gorman sold 7,614 shares of the stock in a transaction dated Tuesday, February 5th. The shares were sold at an average price of $88.16, for a total transaction of $671,250.24. Following the sale, the chief executive officer now directly owns 408,082 shares in the company, valued at $35,976,509.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Kyle Gano sold 3,809 shares of the stock in a transaction dated Tuesday, February 5th. The stock was sold at an average price of $88.12, for a total transaction of $335,649.08. Following the sale, the insider now owns 17,595 shares in the company, valued at $1,550,471.40. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the business. Standard Life Aberdeen plc acquired a new stake in Neurocrine Biosciences during the third quarter worth $16,815,000. GSA Capital Partners LLP acquired a new stake in Neurocrine Biosciences during the third quarter worth $595,000. Pacer Advisors Inc. acquired a new stake in Neurocrine Biosciences during the third quarter worth $327,000. Thrivent Financial for Lutherans increased its stake in Neurocrine Biosciences by 39.9% during the third quarter. Thrivent Financial for Lutherans now owns 355,750 shares of the company’s stock worth $43,739,000 after acquiring an additional 101,517 shares during the last quarter. Finally, Advisors Asset Management Inc. increased its stake in Neurocrine Biosciences by 106.6% during the third quarter. Advisors Asset Management Inc. now owns 7,030 shares of the company’s stock worth $864,000 after acquiring an additional 3,628 shares during the last quarter.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Read More: What is a resistance level?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.